SCM
IOVA icon

Stevens Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Stevens Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-14,391
Closed -$118K – 986
2016
Q3 		$118K Buy
+14,391
New +$122K ﹤0.01% 846
2015
Q4 		– Sell
-15,670
Closed -$90K – 1017
2015
Q3 		$90K Buy
15,670
+4,161
+36% +$32.4K ﹤0.01% 904
2015
Q2 		$106K Buy
+11,509
New +$128K ﹤0.01% 946

Other funds holding IOVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stevens Capital Management's IOVA Position: Q4 2016 in Review

Stevens Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2016, closing a stake of 14,391 shares — an estimated $118K sold.

Stevens Capital Management first reported a position in IOVA in Q2 2015 and held it in 3 quarters. The position peaked at $118K in Q3 2016. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

  • Stevens Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2016 after selling out during the quarter.
  • Stevens Capital Management sold 14,391 Iovance Biotherapeutics shares in Q4 2016, an estimated $118K.
  • Stevens Capital Management first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 3 quarters.
  • Stevens Capital Management's Iovance Biotherapeutics position peaked at $118K in Q3 2016.
  • 87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on Stevens Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.